<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04938726</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-300007323</org_study_id>
    <nct_id>NCT04938726</nct_id>
  </id_info>
  <brief_title>Ketone Supplementation in Cystic Fibrosis</brief_title>
  <official_title>Ketone Monoester Supplementation in Cystic Fibrosis: A Pilot and Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the effects of a novel ketone monester supplement on patients with&#xD;
      cystic fibrosis experiencing an acute pulmonary exacerbation requiring hospitalization.&#xD;
      Patients will undergo standard testing along with blood sampling to examine concentrations of&#xD;
      inflammatory markers. Patients will then receive the ketone supplement for 5 days followed by&#xD;
      post-testing to examine changes in pulmonary function and inflammatory markers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 25 hospitalized patients with cystic fibrosis will take part in this study at UAB.&#xD;
      Patients will be randomly assigned to receive either an exogenous ketone or placebo&#xD;
      supplement. Participants will take the ketone or placebo for 5 days during hospitalization.&#xD;
      Participants will drink one 60 mL bottle twice daily of either the ketone or placebo. On day&#xD;
      1 and day 5, before the patient drinks the ketone (or placebo) the patient will be asked to&#xD;
      fast overnight for 8 hours. Following administration of the first morning dose of ketones (or&#xD;
      placebo) blood samples will be obtained from a finger stick before (time 0 min) and following&#xD;
      (15, 30, 60, 90, and 120 min) after they drink the supplement. A commercially available&#xD;
      ketone meter (Keto-Mojo, Napa, CA) that provides instant assessment of circulating ketone&#xD;
      concentrations will be used to measure ketone concentrations in the blood. Medical history&#xD;
      history will be obtained at hospitalization. The study team will also examine the body for&#xD;
      any abnormal signs and symptoms. Sputum and blood will be collected prior to and following&#xD;
      the ketone supplement or placebo. The hypothesis is that ketone supplementation will reduce&#xD;
      inflammation via a well known inflammatory pathway to improve outcomes in patients with&#xD;
      cystic fibrosis experiencing an acute pulmonary exacerbation&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two-way ANOVA with repeated measures on time</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>All involved with blinded, except for the study pharmacist</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary Function Testing</measure>
    <time_frame>5 days</time_frame>
    <description>FEV1.0 (L/sec)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>5 days</time_frame>
    <description>Interleukin 1Beta (ug/mL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of quality of life, respiratory symptoms, and patient outlook</measure>
    <time_frame>5 days</time_frame>
    <description>A questionnaire will be used to assess quality of life and patient outlook 30 days following the intervention</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Ketone Monoester</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The ketone used is from KetoneAid and is commercially available as KE4 and will be consumed at 30 mL twice daily (15 g / dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A placebo is being manufactured by KetoneAid to match the taste and other characteristics of the ketone supplement for blinding purposes</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ketone Monoester</intervention_name>
    <description>Ketone supplement will be taken by mouth at a dose of 15 mL twice per day</description>
    <arm_group_label>Ketone Monoester</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of CF&#xD;
&#xD;
          -  Age &gt;19&#xD;
&#xD;
          -  Colonization with P. Aeruginosa&#xD;
&#xD;
          -  Acute pulmonary exacerbation requiring inpatient care&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent or recent (within 28 d of enrollment) use of corticosteroids&#xD;
&#xD;
          -  Inability to produce sputum&#xD;
&#xD;
          -  Acute respiratory failure&#xD;
&#xD;
          -  Chronic liver or renal disease&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric P Plaisance, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric P Plaisance, PhD</last_name>
    <phone>205-996-7909</phone>
    <email>plaisep@uab.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kevin R Fontaine, PhD</last_name>
    <phone>205-975-8397</phone>
    <email>kfontai1@uab.edu</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 9, 2021</study_first_submitted>
  <study_first_submitted_qc>June 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Eric P. Plaisance</investigator_full_name>
    <investigator_title>Associate Professor and Chair</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

